- After almost nine years in the position
- Praise and thanks for Heino
- Brian Markison taking over
- Heino will remain as Chair of the Board of Directors at Lantheus
- Heino spoke at length and said 158 words
(exechange) — Bedford, Massachusetts, January 23, 2024 — Mary Anne Heino, chief executive of Lantheus, leaves her position. As announced by Lantheus Holdings Inc. in a news release and in a regulatory filing published on Tuesday, January 23, 2024, Mary Anne Heino leaves her post as chief executive officer at the radiopharmaceutical company, after almost nine years in the role, effective March 1, 2024.
Generally speaking, it raises questions when a CEO leaves her post at short notice.
Mary Anne Heino’s duties as CEO will be taken over by Brian Markison, most recently Chairman of the Board at Lantheus Holdings Inc.
No reason given
In the announcement, Lantheus did not explicitly explain the reason for the move.
Heino will remain as Chair of the Board of Directors at Lantheus
Lantheus stated: “Mary Anne Heino, who has successfully led and grown the Company for the past nine years, will retire as CEO on March 1, 2024 and assume the role of Chair of the Board of Directors as part of a deliberate CEO succession process.”
“Retire”
Lantheus said: “Mary Anne Heino, the Company’s Chief Executive Officer and a member of the Company’s board of directors (the “Board”), notified the Board on January 18, 2024, of her intention to retire as Chief Executive Officer, effective March 1, 2024.”
Share price increase since January 2021
The announcement follows an increase in Lantheus Holdings Inc.’s share price of 298% since January 2021.
In the position of CEO since 2015
Mary Anne Heino became CEO of the Company in 2015.
Mary Anne Heino has served as the Company’s President and Chief Executive Officer and as a Director since August 2015.
She previously served as the Company’s Chief Operating Officer, a position she held from March 2015 until August 2015, and as the Company’s Chief Commercial Officer, a position she held from April 2013 (when she joined the Company) until March 2015.
Heino brings more than 25 years of diverse pharmaceutical industry experience to the Board. Prior to joining Lantheus, Heino led Angelini Labopharm LLC and Labopharm USA in the roles of President and Senior Vice President of WorldWide Sales and Marketing from February 2007 to March 2012.
From May 2000 until February 2007, Heino served in numerous capacities at Centocor, Inc., a Johnson & Johnson (“J&J”) company.
Heino began her professional career with Janssen Pharmaceutica, another J&J company, in June 1989 and worked her way up to the role of Field Sales Director in 1999.
Heino received her Master in Business Administration from the Stern School of Business at New York University.
She earned a Bachelor of Science in Nursing from the City University of New York and a Bachelor’s of Science in Biology from the State University of New York at Stony Brook.
Heino currently serves on the Executive Committee of the Massachusetts Business Roundtable and the Board of MassMEDIC.
158 words by Mary Anne Heino
In the release announcing her departure as CEO of Lantheus Holdings Inc., Mary Anne Heino received praise and thanks.
In announcing her departure, Mary Anne Heino spoke at length and said 158 words.
“Next phase of growth”
Mary Anne Heino stated: “Brian is perfectly suited to lead Lantheus as the Company enters its next phase of growth. He has held the Chair role for more than 10 years and in that role has overseen Company strategy. He knows our exceptional Executive Team well and brings decades of leadership experience as the CEO of public companies with development, commercialization and manufacturing expertise, including in oncology and neurology therapeutics. It has been my honor to lead Lantheus over the past nine years, and I am extremely proud of what we have accomplished. Our leadership as a radiopharmaceutical-focused company and the contributions Lantheus has made to precision diagnostics have aided healthcare providers and their patients around the world. We have an incredibly talented team at Lantheus, and I look forward to serving as Chair and continuing to partner closely with Brian and the Executive Team as we focus on our Purpose to Find, Fight and Follow disease to deliver better patient outcomes.”
Push-out Score for Mary Anne Heino’s move determined
The Push-out Score™ determined by exechange gauges the pressure surrounding Mary Anne Heino’s move on a scale of 0 to 10.
Read the full story in the exechange report 5.2024 ($).